顺势疗法治疗初级保健中Covid-19:随机对照试验方案结构化摘要
该随机双盲安慰剂对照试验旨在评估顺势疗法药物Natrum muriaticum(LM2)对初级保健中轻症COVID-19的有效性和安全性。
要点
- 评估Natrum muriaticum LM2对轻症COVID-19的疗效与安全性。
- 主要终点为所有流感样症状记录为轻度或消失的恢复时间。
核心结论
- 该试验旨在验证顺势疗法药物Natrum muriaticum LM2对轻症COVID-19是否优于安慰剂,目前尚未报告结果。
研究设计与样本
- 随机、两臂(1:1)、平行、安慰剂对照、双盲临床试验,在巴西圣保罗州圣卡洛斯初级保健机构进行。
- 随机化由统计学家使用区组随机列表和网络工具生成,比例为1:1。
- 临床研究者、统计学家、初级保健团队、研究合作者和参与者均保持盲态直至研究结束。
关键数值与推荐
- 干预组:Natrum muriaticum LM2 1丸稀释于20 mL 30%酒精中,装入30 mL瓶;对照组:20 mL 30%酒精装入30 mL瓶。
- 每次给药前药瓶需剧烈震荡(succussions)10次;给药方案可通过远程医疗调整而不打破盲法。
- 主要终点:居家隔离期间所有COVID-19流感样症状记录为轻度或消失前的天数。
- 次要指标:各症状恢复时间、COVID-Simile量表评分、随访期间用药、随访天数、急诊就诊次数、住院次数、其他症状及不良事件。
临床怎么用
- 研究期间研究药物应在居家隔离期间维持使用;居家隔离持续至首发症状后第10天或无症状达72小时。
局限性
- 该文献为研究方案摘要,尚未报告试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care. TRIAL DESIGN: A randomized, two-armed (1:1), parallel, placebo-controlled, double-blind, clinical trial is being performed to test the following hypotheses: H0: homeopathic medicines = placebo (null hypothesis) vs. H1: homeopathic medicines ≠ placebo (alternative hypothesis) for mild cases of COVID-19 in Primary Care. PARTICIPANTS: Setting: Primary Care of São Carlos - São Paulo - Brazil. One hundred participants aged 18 years or older, with Influenza-like symptoms and a positive RT-PCR for SARS-CoV-2. Willingness to give informed consent and to comply with the study procedures is also required. Exclusion criterium: severe acute respiratory syndrome. INTERVENTION AND COMPARATOR: Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30% and dispensed in a 30 ml bottle. Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle. Posology: one drop taken orally every 4 hours (6 doses/day) while there is fever, cough, tiredness, or pain (headache, sore throat, muscle aches, chest pain, etc.) followed by one drop every 6 hours (4 doses/day) until the fourteenth day of use. The bottle of study medication should be submitted to 10 vigorous shakes (succussions) before each dose. Posology may be changed by telemedicine, with no break in blinding. Study medication should be maintained during home isolation. According to the Primary Care protocol, the home isolation period lasts until the 10th day after the appearance of the first symptom, or up to 72 hours without symptoms. MAIN OUTCOMES: The primary endpoint will be time to recovery, defined as the number of days elapsed before all COVID-19 Influenza-like symptoms are recorded as mild or absent during home isolation period. Secondary measures are recovery time for each COVID-19 symptom; score of the scale created for the study (COVID-Simile Scale); medicines used during follow-up; number of days of follow-up; number of visits to emergency services; number of hospitalizations; other symptoms and Adverse Events during home isolation period. RANDOMISATION: The study Statistician generated a block randomization list, using a 1:1 ratio of the two groups (denoted as A and B) and a web-based tool ( http://www.random.org/lists ). BLINDING (MASKING): The clinical investigators, the statistician, the Primary Care teams, the study collaborators, and the participants will remain blinded from the identity of the two treatment groups until the end of the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): One hundred participants are planned to be randomized (1:1) to placebo (50) or homeopathy (50). TRIAL STATUS: Protocol version/date May 21, 2020. Recruitment is ongoing. First participant was recruited/included on June 29,2020. Due to recruitment adaptations to Primary Care changes, the authors anticipate the trial will finish recruiting on April 10, 2021. TRIAL REGISTRATION: COVID-Simile Study was registered at the University Hospital Medical Information Network (UMIN - https://www.umin.ac.jp/ctr/index.htm ) on June 1st, 2020, and the trial start date was June 15, 2020. Unique ID: UMIN000040602. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Adler UC, Adler MS, Hotta LM, et al. Homeopathy for Covid-19 in Primary Care: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 33522951. doi:10.1186/s13063-021-05071-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。